NasdaqCM:VKTXBiotechs
Viking Therapeutics (VKTX) Raises Fresh Capital After Wider Losses, Is It Still Undervalued?
Viking Therapeutics (VKTX) is back in focus after reporting wider second quarter losses alongside a series of at the market equity offerings and a new universal shelf registration that increase its funding flexibility.
See our latest analysis for Viking Therapeutics.
Viking Therapeutics' share price has eased in the short term, with a 30 day share price return down 21%, while the 3 year total shareholder return of about 124% and 5 year total shareholder return above 7x show a very strong...